Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Huisarts en wetenschap 8/2011

01-08-2011 | Nascholing

Nieuwe ontwikkelingen bij de behandeling van coloncarcinoom

Auteur: dr. M. Koopman

Gepubliceerd in: Huisarts en wetenschap | Uitgave 8/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Koopman M. Nieuwe ontwikkelingen bij de behandeling van coloncarcinoom. Huisarts Wet 2001;54(8):450-4.
Het colorectaal carcinoom (CRC) is één van de meest voorkomende vormen van kanker in Nederland; in de praktijk van de gemiddelde huisarts krijgen jaarlijks ongeveer twee patiënten de diagnose. Belangrijke risicofactoren zijn leeftijd (ouder dan 50), weinig lichaamsbeweging, ongezonde voeding en overgewicht. Patiënten zonder metastasen (stadia I-III) komen in aanmerking voor een in opzet curatieve behandeling, met een redelijk goede prognose. Ongeveer de helft van alle patiënten ontwikkelt uiteindelijk toch metastasen en krijgt palliatieve systemische therapie. Van belang voor de huisarts zijn vooral de bijwerkingen van fluoropyrimidines, oxaliplatine en irinotecan, en die van nieuwe ‘targeted’ middelen zoals bevacizumab, cetuximab en panitumumab. Het onderzoek richt zich momenteel vooral op de identificatie van predictieve factoren die tot een betere selectie van patiënten voor deze behandelingen moeten gaan leiden.

Met onderstaand(e) abonnement(en) heeft u direct toegang:

DocsOnline – Vakinformatie voor huisartsen

Met DocsOnline blijft u op de hoogte van de actuele ontwikkelingen in uw vak en bouwt u efficiënt aan uw vakkennis. U krijgt digitale toegang tot zo'n 30 boeken huisartsgeneeskunde en 3 vaktijdschriften. Alles om u nóg beter te maken in uw vak.

Huisarts en Wetenschap

Dit vierwekelijks verschijnend tijdschrift van het Nederlands Huisartsen Genootschap (NHG) geeft informatie die een bijdrage levert aan het wetenschappelijk fundament van de huisartsgeneeskunde.

Proefabonnement BSL Huisarts Totaal

Met BSL Huisarts Totaal bouwt u efficiënt aan uw vakkennis. U krijgt digitale toegang tot boeken, veelgestelde vragen, casuïstiek en zes vaktijdschriften voor huisartsen. Met het proefabonnement krijgt u toegang tot: één geaccrediteerde web-tv en tien interessante boektitels. 


BSL Huisarts Totaal 1 maand gratis:  € 0,-

Literatuur
1.
go back to reference Van Steenbergen LN. Zorg voor darmkankerpatiënten in Zuid-Nederland verder verbeterd. Ned Tijdschr Oncol 2010;7:310–3. Van Steenbergen LN. Zorg voor darmkankerpatiënten in Zuid-Nederland verder verbeterd. Ned Tijdschr Oncol 2010;7:310–3.
2.
go back to reference World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: A global perspective. Washington DC: AIRC, 2007. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: A global perspective. Washington DC: AIRC, 2007.
3.
go back to reference O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons jr RJ, Erlichman C, Shepherd LE, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patiënts with high-risk colon cancer. J Clin Oncol 1998;16:295–300. PubMed O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons jr RJ, Erlichman C, Shepherd LE, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patiënts with high-risk colon cancer. J Clin Oncol 1998;16:295–300. PubMed
4.
go back to reference Punt CJA. Medicamenteuze behandeling van patiënten met colorectumcarcinoom. Ned Tijdschr Geneeskd 2005;149:1441–7. PubMed Punt CJA. Medicamenteuze behandeling van patiënten met colorectumcarcinoom. Ned Tijdschr Geneeskd 2005;149:1441–7. PubMed
5.
go back to reference Gray RG, Barnwell J, Hills R, McConkey C, Willimas N, Kerr D. QUASAR: Adjuvant chemotherapy vs observation in patiënts with colorectal cancer; a randomised study. Lancet 2007;370:2020–9. PubMedCrossRef Gray RG, Barnwell J, Hills R, McConkey C, Willimas N, Kerr D. QUASAR: Adjuvant chemotherapy vs observation in patiënts with colorectal cancer; a randomised study. Lancet 2007;370:2020–9. PubMedCrossRef
6.
go back to reference André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16. PubMedCrossRef André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16. PubMedCrossRef
7.
go back to reference Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment of stage III colon cancer. N Engl J Med 2005;352:2696–704. PubMedCrossRef Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment of stage III colon cancer. N Engl J Med 2005;352:2696–704. PubMedCrossRef
8.
go back to reference Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine and oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patiënts. J Clin Oncol 2007;25:102–9. PubMedCrossRef Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine and oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patiënts. J Clin Oncol 2007;25:102–9. PubMedCrossRef
9.
go back to reference Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the olon: Results of NSABP Protocol C-08. J Clin Oncol 2009;27:18s (abstr. LBA4). Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the olon: Results of NSABP Protocol C-08. J Clin Oncol 2009;27:18s (abstr. LBA4).
10.
go back to reference Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patiënts (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010;28:15s (abstr. 3508). Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patiënts (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010;28:15s (abstr. 3508).
11.
go back to reference Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42. PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42. PubMedCrossRef
12.
go back to reference Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83. PubMedCrossRef Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83. PubMedCrossRef
13.
go back to reference Koopman M, Muller EW, Punt CJA. Reversible posterior leukoencephalopathy syndrome due to bevacizumab. Dis Colon Rectum 2008;51:1425–6. PubMedCrossRef Koopman M, Muller EW, Punt CJA. Reversible posterior leukoencephalopathy syndrome due to bevacizumab. Dis Colon Rectum 2008;51:1425–6. PubMedCrossRef
14.
go back to reference Modulation of fluorouracil by leucovorin in patiënts with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896–903. Modulation of fluorouracil by leucovorin in patiënts with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896–903.
15.
go back to reference Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patiënts with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–92. PubMed Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patiënts with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–92. PubMed
16.
go back to reference Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patiënts with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106. PubMed Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patiënts with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106. PubMed
17.
go back to reference Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patiënts with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605–16. PubMedCrossRef Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patiënts with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605–16. PubMedCrossRef
18.
go back to reference Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patiënts with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617–27. PubMedCrossRef Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patiënts with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617–27. PubMedCrossRef
19.
go back to reference therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566–75. PubMedCrossRef therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566–75. PubMedCrossRef
20.
go back to reference Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190–7. PubMedCrossRef Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190–7. PubMedCrossRef
21.
go back to reference Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135–42. PubMedCrossRef Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135–42. PubMedCrossRef
22.
go back to reference Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patiënts with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007;370:143–52. PubMedCrossRef Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patiënts with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007;370:143–52. PubMedCrossRef
23.
go back to reference Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patiënts with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14. PubMedCrossRef Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patiënts with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14. PubMedCrossRef
24.
go back to reference Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first- line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–9. PubMedCrossRef Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first- line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–9. PubMedCrossRef
25.
go back to reference Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patiënts with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9. PubMedCrossRef Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patiënts with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9. PubMedCrossRef
26.
go back to reference Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357: 2040–8. PubMedCrossRef Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357: 2040–8. PubMedCrossRef
27.
go back to reference Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45. PubMedCrossRef Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45. PubMedCrossRef
28.
go back to reference Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17. PubMedCrossRef Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17. PubMedCrossRef
Metagegevens
Titel
Nieuwe ontwikkelingen bij de behandeling van coloncarcinoom
Auteur
dr. M. Koopman
Publicatiedatum
01-08-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 8/2011
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/s12445-011-0211-z